# Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)

> **NCT00095576** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 3000 (actual)

## Conditions studied

- AIDS
- HIV Infections

## Interventions

- **BIOLOGICAL:** Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)
- **DRUG:** Comparator: placebo

## Key facts

- **NCT ID:** NCT00095576
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-11
- **Primary completion:** 2007-09
- **Final completion:** 2009-09
- **Target enrollment:** 3000 (ACTUAL)
- **Last updated:** 2015-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095576, "Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00095576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*